We appreciate Lai and colleagues’ interest in our study in which we reported associations between aspirin use and gastric adenocarcinoma in two large prospective cohort studies of U.S. men and women (1). Lai and colleagues calculated that comparing aspirin users with nonusers, the absolute rate difference was 2/100,000 person-years with a number-needed-to-treat (NNT) of 50,000 in women. Perhaps a more clinically interpretable metric of absolute risk would be based on persons at risk rather than person-years using an estimate calculated according to the mean follow-up time (30.6 years) of cohort participants. We would then estimate the risk of gastric cancer was 0.0018 [125 cases/(2,097,414 person-years/30.6 years)] among nonregular aspirin users, and 0.0012 [51 cases/(1,258,158 person-years/30.6 years)] among regular users. This translates to an NNT of 1,714, suggesting one case of gastric cancer could potentially be prevented by treating 1,714 women with aspirin regularly. Nonetheless, we concur that public...
Skip Nav Destination
Article navigation
1 August 2022
Letters to the Editor|
August 01 2022
Aspirin Use and Gastric Adenocarcinoma—Reply
Wenjie Ma
;
Wenjie Ma
1Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
Search for other works by this author on:
Andrew T. Chan
Andrew T. Chan
*
1Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
*Corresponding Author: Andrew T. Chan, Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114. Phone: 617-726-7802; Fax: 617-726-3673; E-mail: [email protected]
Search for other works by this author on:
*Corresponding Author: Andrew T. Chan, Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114. Phone: 617-726-7802; Fax: 617-726-3673; E-mail: [email protected]
Cancer Prev Res 2022;15:555–6
Received:
June 13 2022
Revision Received:
June 16 2022
Accepted:
June 16 2022
Online ISSN: 1940-6215
Print ISSN: 1940-6207
©2022 American Association for Cancer Research
2022
American Association for Cancer Research
Cancer Prev Res (Phila) (2022) 15 (8): 555.
Article history
Received:
June 13 2022
Revision Received:
June 16 2022
Accepted:
June 16 2022
Related Content
A commentary has been published:
Aspirin Use and Gastric Adenocarcinoma—Letter
Citation
Wenjie Ma, Andrew T. Chan; Aspirin Use and Gastric Adenocarcinoma—Reply. Cancer Prev Res (Phila) 1 August 2022; 15 (8): 555. https://doi.org/10.1158/1940-6207.CAPR-22-0281
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Pay-Per-View 24-Hour Access
$50.00
405
Views
Citing articles via
Advertisement